FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2898028823> ?p ?o ?g. }

• W2898028823 endingPage "e116" @default.
• W2898028823 startingPage "e116" @default.
• W2898028823 abstract "We report clinical efficacy and safety on subset analysis of atrial fibrillation patients in the Case Review of the Penumbra and Indigo Systems for Mechanical Thrombectomy in the Periphery (PRISM) trial. This trial examined efficacy and safety of XTRACT (a power aspiration-based extraction technique) using the Penumbra Indigo System (Penumbra Inc, Alameda, Calif) as a frontline and secondary treatment of peripheral arterial occlusions. The PRISM trial was a single-arm, multicenter, retrospective analysis of patients with acute or subacute arterial occlusions who met the inclusion criteria of peripheral arterial occlusion (Thrombolysis in Myocardial Infarction [TIMI] 0-1) before attempted endovascular treatment using XTRACT. The primary end points were vessel patency immediately after XTRACT and after any other subsequent endovascular procedure as measured by TIMI score as well as the rate of procedural serious adverse events within 24 hours of treatment. PRISM included a total of 79 patients. Among these patients, XTRACT was the primary treatment modality for 49.4% (39/79); 50.6% (40/79) were treated with XTRACT secondary to failure of catheter-directed thrombolysis, other endovascular therapies, and distal emboli from preceding interventions. Overall, vessel patency (TIMI 2-3) among these patients was achieved in 87.2% (68/78) immediately after XTRACT and in 96.2% (76/79) of patients after additional adjunctive interventions. In this subgroup analysis of patients with atrial fibrillation (n = 12), 66.7% were female. XTRACT was the primary treatment modality for seven patients (58.3%), whereas the remaining five patients (41.7%) were treated with XTRACT secondary to failure of catheter-directed thrombolysis or other endovascular therapies. Frontline XTRACT was successful in 71.4% (5/7) of patients; however, as secondary therapy, 100% (5/5) of patients were successfully revascularized to TIMI 2-3. Overall, vessel patency (TIMI 2-3) was achieved in 83.3% immediately after XTRACT and in 100% of patients after additional adjunctive interventions. Overall, procedural serious adverse events within 24 hours were reported in 8.9% (7/79) of patients overall and 8.3% (1/12) of patients with atrial fibrillation. None were device related. Penumbra Indigo system using XTRACT technique is a safe and effective intervention in atrial fibrillation patients with underlying peripheral arterial occlusions. XTRACT was useful both as a frontline therapy and as a salvage technique when other endovascular techniques or thrombolysis had failed. Future prospective trials are needed." @default.
• W2898028823 created "2018-10-26" @default.
• W2898028823 creator A5011108372 @default.
• W2898028823 creator A5049418015 @default.
• W2898028823 creator A5049792406 @default.
• W2898028823 creator A5085052382 @default.
• W2898028823 creator A5086737942 @default.
• W2898028823 date "2018-11-01" @default.
• W2898028823 modified "2023-09-28" @default.
• W2898028823 title "LEA 7. Efficacy of XTRACT on Atrial Fibrillation Patients With Peripheral Arterial Disease: Subset Analysis from PRISM Trial" @default.
• W2898028823 doi "https://doi.org/10.1016/j.jvs.2018.08.018" @default.
• W2898028823 hasPublicationYear "2018" @default.
• W2898028823 type Work @default.
• W2898028823 sameAs 2898028823 @default.
• W2898028823 citedByCount "0" @default.
• W2898028823 crossrefType "journal-article" @default.
• W2898028823 hasAuthorship W2898028823A5011108372 @default.
• W2898028823 hasAuthorship W2898028823A5049418015 @default.
• W2898028823 hasAuthorship W2898028823A5049792406 @default.
• W2898028823 hasAuthorship W2898028823A5085052382 @default.
• W2898028823 hasAuthorship W2898028823A5086737942 @default.
• W2898028823 hasBestOaLocation W28980288231 @default.
• W2898028823 hasConcept C120665830 @default.
• W2898028823 hasConcept C121332964 @default.
• W2898028823 hasConcept C126322002 @default.
• W2898028823 hasConcept C164705383 @default.
• W2898028823 hasConcept C2777466421 @default.
• W2898028823 hasConcept C2779161974 @default.
• W2898028823 hasConcept C3018348675 @default.
• W2898028823 hasConcept C46762472 @default.
• W2898028823 hasConcept C67666897 @default.
• W2898028823 hasConcept C71924100 @default.
• W2898028823 hasConceptScore W2898028823C120665830 @default.
• W2898028823 hasConceptScore W2898028823C121332964 @default.
• W2898028823 hasConceptScore W2898028823C126322002 @default.
• W2898028823 hasConceptScore W2898028823C164705383 @default.
• W2898028823 hasConceptScore W2898028823C2777466421 @default.
• W2898028823 hasConceptScore W2898028823C2779161974 @default.
• W2898028823 hasConceptScore W2898028823C3018348675 @default.
• W2898028823 hasConceptScore W2898028823C46762472 @default.
• W2898028823 hasConceptScore W2898028823C67666897 @default.
• W2898028823 hasConceptScore W2898028823C71924100 @default.
• W2898028823 hasIssue "5" @default.
• W2898028823 hasLocation W28980288231 @default.
• W2898028823 hasOpenAccess W2898028823 @default.
• W2898028823 hasPrimaryLocation W28980288231 @default.
• W2898028823 hasRelatedWork W1750570115 @default.
• W2898028823 hasRelatedWork W1965964500 @default.
• W2898028823 hasRelatedWork W1970230662 @default.
• W2898028823 hasRelatedWork W1994785581 @default.
• W2898028823 hasRelatedWork W2034606391 @default.
• W2898028823 hasRelatedWork W2065421515 @default.
• W2898028823 hasRelatedWork W2085641168 @default.
• W2898028823 hasRelatedWork W2177388045 @default.
• W2898028823 hasRelatedWork W2304633692 @default.
• W2898028823 hasRelatedWork W3028901408 @default.
• W2898028823 hasVolume "68" @default.
• W2898028823 isParatext "false" @default.
• W2898028823 isRetracted "false" @default.
• W2898028823 magId "2898028823" @default.
• W2898028823 workType "article" @default.